首页 | 官方网站   微博 | 高级检索  
     

从生产者角度分析药品临床供应短缺的原因
引用本文:周振,冯国忠.从生产者角度分析药品临床供应短缺的原因[J].中国药事,2017,31(6):596-599.
作者姓名:周振  冯国忠
作者单位:中国药科大学国际医药商学院, 南京 211198,中国药科大学国际医药商学院, 南京 211198
摘    要:目的:从生产者角度分析药品短缺原因,提出应对药品短缺问题的政策建议。方法:采用文献综述法和归纳总结法,分析药品短缺原因;在此基础上提出相关建议。结果与结论:对于药品生产企业来说,药品短缺原因分为生产原因和非生产原因。生产性原因分为主观原因和客观原因。主观原因主要有价格太低、需求量少、成本上升等造成企业不愿生产;客观原因主要有原料获取困难、生产条件不符合规定等。非生产性原因主要有流通环节利润太低、流通垄断、意外情况等。应进一步调动生产企业积极性、净化原料和流通环节、落实保障政策,提高相应药品的可及性。

关 键 词:生产企业  药品短缺  利润  价格  原料获取  流通渠道  政策建议
收稿时间:2017/1/5 0:00:00

Analysis of the Causes of Shortage of Clinical Drug Supply from the Viewpoint of Manufacturers
Zhou Zhen and Feng Guozhong.Analysis of the Causes of Shortage of Clinical Drug Supply from the Viewpoint of Manufacturers[J].Chinese Pharmaceutical Affairs,2017,31(6):596-599.
Authors:Zhou Zhen and Feng Guozhong
Affiliation:College of International Medical Business, China Pharmaceutical University, Nanjing 211198, China and College of International Medical Business, China Pharmaceutical University, Nanjing 211198, China
Abstract:Objective: To analyze the causes of drug shortage from the viewpoint of manufacturer and put forward policy suggestions to deal with the drug shortage. Methods: The causes of drug shortage were analyzed using methods of literature review and induction, and relevent suggestions were put forward. Results and Conclusion: As far as drug manufacturers are concerned, the causes of drug shortage are divided into production reasons which are divided into subjective reasons and objective reasons and non-production reasons which include low distribution proft, distribution monopoly, accidents and so on. The main subjective reasons include too low prices, low demand, as well as rising costs, with the result that manufacturers are unwilling to produce. The main objective reasons include the shortage of raw materials and the unqualifed requirements for production conditions. Government should further mobilize the enthusiasm of drug manufacturers, clarifcation of raw material market and distribution, implement security policies and other measures to improve the accessibility of the corresponding drugs.
Keywords:manufacturers  drug shortage  proft  price  raw material acquisition  distribution channel  policy suggestions
点击此处可从《中国药事》浏览原始摘要信息
点击此处可从《中国药事》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号